24/7
Buzz
Startups
VC
@work
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Multiple Sclerosis
Tags search
HOME
24/7
buzz
STARTUPS
VC
Tech@work
Innovation
OPINIONS
EVENTS
ABOUT
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:30
CyberArk founder: "The process of building a high-tech company is full of endless failures"
14:18
Deloitte Launchpad announces 5th cohort with 10 new startups
12:40
Major TAU benefactor to consider halting investments over judicial reform
12:18
Minute Media eyeing more acquisitions, becoming profitable, says CEO
More stories
Buzz
Most popular
Daily
Weekly
1
Deloitte Launchpad announces 5th cohort with 10 new startups
2
Creator investment platform Exceed raises $8 million Seed round
3
"Investments in Israel have all but disappeared - also because of the judicial coup”
4
The 50 most promising Israeli startups - 2022
5
daily.dev raises $11 million in Seed funding to build a professional network for developers
More news
Multiple Sclerosis
2 stories about Multiple Sclerosis
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market
31.10.17
|
Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
Please ensure Javascript is enabled for purposes of
website accessibility